

Small-molecule RETRA is effective against a fatal childhood cancer

The bone tumor Ewing's sarcoma is one of the most aggressive cancers in childhood and adolescence. Before the era of chemotherapy, more than 90% of Ewing's sarcoma patients succumbed to their disease. With the introduction of intensive treatment consisting of multi-agent chemotherapy in conjunction with surgery and/or radiation, survival rates in patients with localized tumors have increased to approximately 75% in high-income countries. However, the prognosis for the about 25% of patients with detectable metastases at diagnosis is still dismal, with only 10-40% survivors, depending on the site of metastasis. Even worse, of the patients who experience disease relapse, not more than 10% are cancer free at five years follow-up. The outcome for patients with metastasized or recurrent Ewing's sarcoma, thus, is very disappointing, and new therapeutic approaches for these patients are clearly needed.




Fig. 1. RETRA induces cancer cell death in Ewing's sarcoma cells with mutant p53. Ewing's sarcoma cells were treated with increasing concentrations of RETRA for 48 h.

An intriguing new strategy to improve anticancer therapy is drugging a protein known as p53. The principal tumor-suppressor protein p53 is probably the most important molecule in cancer. This is highlighted by the fact that about half of human cancers have inactivating mutations of p53, making it the most commonly mutated protein in human cancers. p53 is less frequently mutated in Ewing's sarcoma, however, the subset of Ewing's sarcoma patients with mutant p53 is very unresponsive to

chemotherapy and has a significantly poorer outcome than average. Therefore, Ewing's sarcoma with mutant p53 represents a particular challenge in the management of patients with this disease.

In the new study, a novel anticancer compound, termed RETRA, was investigated for its effectiveness against Ewing's sarcoma in a number of cell line models with either healthy or mutant p53. RETRA was found to be effective against Ewing's sarcoma cells completely independent of their p53 status. These results point to RETRA's potential as an effective therapeutic strategy for patients with Ewing's sarcoma, including those with mutant p53. Notably, in previous studies, RETRA has been reported to not affect normal cells with normal p53. RETRA thus may be effective against Ewing's sarcoma without inflicting collateral damage on normal tissue.

Publication

[RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status.](#)

Sonnemann J, Grauel D, Blümel L, Hentschel J, Marx C, Blumrich A, Focke K, Becker S, Wittig S, Schinkel S, Krämer OH, Beck JF.

Eur J Cancer. 2015 May